摘要
目的分析C-Kit、PDGFRα在卵巢浆液性癌中的表达及其与铂类耐药的关系,以期为顺铂耐药的卵巢癌治疗提供实验室依据。方法采用免疫组化SP法检测C-Kit、PDGFRα在59例卵巢浆液性癌中的表达,并分析两者的表达与卵巢浆液性癌顺铂耐药的关系。结果C-Kit、PDGFRα在59例卵巢浆液性癌中的阳性表达率分别为57.63%和66.10%。C-Kit蛋白阳性表达与卵巢浆液性癌化疗铂类耐药有关(P<0.05),而PDGFRα蛋白阳性表达与卵巢浆液性癌化疗铂类耐药无关(P>0.05)。C-Kit、PDGFRα的表达与卵巢浆液性癌组织学分级和临床分期有关(P<0.01或P<0.05)。结论C-Kit蛋白阳性表达与卵巢浆液性癌顺铂耐药有关,而PDGFRα表达与卵巢浆液性癌顺铂耐药无关。
Objective To investigate the expressions of C-Kit and PDGFRα and their correlation with chemotherapy resistance in ovarian serous carcinomas. Methods We undertook SP immunohistochemical technique to examine the expressions of C-Kit and PDCJFRα in 59 cases with ovarian serous carcinomas, usng archival paraffinembedded specimens. Then we observed the correlation with chemotherapy resist ante. Results C-Kit and PDGFRα immunostainings were observed positively expressed in 57. 63% and 66. 10% of cases. C-Kit expression was statistically correlated with progression of disease after first-line chemotherapy （P〈0. 05）, but PDGFRα was not statistically significant （P〉0. 05）. There were great difference between of CKit and PDGFRα expressions in samples of different differentiated and clinical stages of ovarian serous carcinomas （P〈0. 01 or P〈0. 05）. Conclusion C-Kit is statistically correlated with chemotherapy resistance,while PDGFRα is not correlated.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
2008年第11期805-807,共3页
Cancer Research on Prevention and Treatment
基金
湖北省卫生厅科研基金指导性项目(JX3C54)
